Today: 8 February 2026
Subscribe
Browse Category

Biotechnology News 17 January 2026 - 25 January 2026

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences shares rose about 2% premarket after an SEC filing showed FDA agreement on a single adaptive Phase 2/3 trial for its Gemini program in acute kidney injury. The company said strong results from roughly 300 patients could support a U.S. approval filing. Shares last traded near $0.85. Investors remain focused on trial timing and the firm’s $12.7 million cash position.
23 January 2026
··
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
··
Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

Regencell Bioscience shares jumped 16.3% to $35.77 in premarket trading Friday after a 40.4% surge Thursday, with no new company announcements. Thursday’s rally saw heavy volume and wide price swings, closing at $30.77. The company’s filings warn of “extreme price and volume fluctuations” and note it has no saleable products or revenue. Market cap reached about $15.2 billion as of Friday.
23 January 2026
··
CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL Ltd shares closed 0.7% higher at A$179.62 Friday, extending Thursday’s gains, with 1.01 million shares traded. The stock’s rise comes as U.S. vaccine policy changes under Health Secretary Robert F. Kennedy Jr. weigh on sentiment for CSL’s Seqirus unit. CSL delayed a Seqirus spinoff and cut its 2026 growth forecast in October, citing falling U.S. flu vaccination rates. Half-year results are due Feb. 11.
23 January 2026
···
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna shares jumped 4.2% to $51.87 in after-hours trading Thursday after CEO Stephane Bancel said the company will halt new late-stage vaccine trials, citing resistance from U.S. officials and an unreliable U.S. market. The move follows weak COVID vaccine demand and comes as Moderna and Merck reported their experimental cancer vaccine cut melanoma recurrence or death by 49% over five years in a mid-stage study.
23 January 2026
··
GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus

GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus

GRAIL shares jumped 13.2% to $114.41 Thursday, hitting an intraday high of $118.50 amid investor focus on cash burn and 2026 growth targets. The company projects 2025 revenue of $147–$148 million and aims to cut cash burn to $274 million. Key milestones include a modular FDA submission in Q1 and major clinical trial readouts by mid-2026. Investors are also watching the closing of a $110 million Samsung investment.
22 January 2026
·
Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Thermo Fisher shares rose $2.03 to $638.33 Thursday afternoon, trading near a 52-week high after closing Wednesday at $636.30. Investors are watching for fourth-quarter and full-year results due Jan. 29. The company recently delisted its 3.200% senior notes due 2026 from the NYSE. Thermo Fisher earlier announced a collaboration with Nvidia on AI-based lab automation tools.
22 January 2026
··
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
··
Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex Pharmaceuticals shares rose 4.31% to $461.14, extending gains for a third session with trading volume above the 50-day average. The company will report fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call. Director Bruce I. Sachs received 107.088 deferred stock units, according to a Jan. 15 regulatory filing.
22 January 2026
···
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
··
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals shares fell 8% to $19.68 in premarket trading Wednesday after announcing a $150 million stock-and-warrant offering. The drop follows a 167% surge Tuesday on positive Phase 1 data for soquelitinib in atopic dermatitis. Corvus paused its $100 million at-the-market share sales facility ahead of the new deal. No severe adverse events were reported in the trial.
21 January 2026
···
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck shares traded near $108.82 Tuesday after Merck and Moderna reported their personalized melanoma vaccine with Keytruda cut recurrence or death risk by 49% over five years in a phase 2b trial. The stock showed little change following the update. More data will be presented at a future medical meeting. Investors await Merck’s Feb. 3 earnings call for further details on its oncology portfolio.
20 January 2026
····
Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

Qiagen stock price jumps nearly 16% as Bloomberg report revives sale talk

Qiagen shares jumped 15.9% to $55.13 in U.S. trading Tuesday after reports the diagnostics firm is exploring strategic options, including a potential sale, and has hired advisers. Bloomberg said the company’s board is handling new takeover interest, but talks remain preliminary. Qiagen will report fourth-quarter results Feb. 4, with a conference call set for Feb. 5. The company has not commented on the reports.
20 January 2026
··
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio shares surged 39.8% Friday after reporting a 750% jump in 2025 ANKTIVA sales and new regulatory approvals, including in Saudi Arabia. The company said its pivotal bladder cancer trial is over 85% enrolled, with completion targeted for Q2 2026. ImmunityBio ended the quarter with $242.8 million in cash. Investors await audited 2025 results and further updates on ANKTIVA and CAR-NK programs.
17 January 2026
···
1 2 3 4 … 15

Stock Market Today

Renesas stock price jumps again as $3 billion SiTime deal keeps traders hooked on 6723

8 February 2026
TOKYO, Feb 8, 2026, 10:10 JST — Market closed. Renesas Electronics shares ended Friday up 6.9% at 2,957.5 yen, extending a two-session rally that left the stock about 15% higher heading into the weekend. (Investing.com) With Tokyo shut on Sunday, the near-term question is simple: does that bounce hold when trading resumes on Monday, or does it fade once the headlines thin out? It matters now because Renesas sits deep in automotive and industrial supply chains, and its fresh guidance lands as investors try to map where chip demand is firming — and where it is still stuck. A notice
Moore Threads (688795) share price in focus after Pony.ai tie-up as China market reopens

Moore Threads (688795) share price in focus after Pony.ai tie-up as China market reopens

8 February 2026
Moore Threads’ Shanghai-listed shares closed up 0.45% at 536.99 yuan on Feb. 6 after announcing a strategic cooperation with Pony.ai on autonomous driving compute. Pony.ai plans to use Moore Threads’ MTT S5000 cards for L4 system training and targets over 3,000 Robotaxis by end-2026. Investors await further deal details as the market reopens Monday.
NXP stock heads into Monday after $3 billion credit line refresh — what to watch for NXPI

NXP stock heads into Monday after $3 billion credit line refresh — what to watch for NXPI

8 February 2026
NXP Semiconductors shares closed up 1% at $224.32 Friday after subsidiaries amended a $3 billion revolving credit deal with Barclays, maturing in 2031. The PHLX semiconductor index surged 5.7% as chip stocks rallied on AI spending signals from Amazon and Alphabet. NXP’s gain lagged peers like Monolithic Power, which rose 6.4%. Investors await U.S. jobs and inflation data next week.
Go toTop